Indeed, the BMP inhibitor DM was first identified by its dorsalising effects in embryonic zebrafish [12], and analogues of DM that can target Acvr1 are now repurposed (from being a leukaemia therapy) and in clinical trials to prevent the ectopic mineralisation seen in FOP [24]. The gene discussed is ACVR1; the disease is leukemia.